semaglutide princeton GLP-1 Receptor Agonist Research Reference Semaglutide: The Skinny Shot in

Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications

Hydration Support: Helps maintain moisture for soft, supple-looking skin

news outlets have documented millions of weight-loss drug prescriptions and the strain on insurers and patients

What Are the Benefits of Alpha Lipoic Acid

Other ingredients with metabolic effects Several other compounds commonly included in GLP-1 support supplements show varying degrees of evidence